Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 3M Company (MMM) vs Viatris Inc (VTRS) Price & Performance

3M CompanyTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

3M Company vs Viatris Inc — how do they compare? 3M Company trades at $163.61 (market cap $84.36B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: 3M Company is far larger — about 4.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Viatris Inc for 57 Days on average.

MMMVTRS
Market Cap
$84.36B$20.03B
Volume
2,325,30114,109,977
Sector
IndustrialsHealth
52-Week High
$183.79$18.27
52-Week Low
$141.10$9.74
Typical Hold Time
169 Days57 Days
Enterprise Value
$93.58B$32.15B
Dividend Yield
1.91%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

3M Company

MMM trades at $162.12, down 0.93% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a robust net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while recent news highlights operational turnaround progress and litigation management.

The outlook balances solid fundamentals against high debt and weak consumer demand. Upside potential exists from industrial strength and shareholder returns, but risks include cost pressures and macroeconomic headwinds. The stock's current valuation at a P/E of 28.8 requires sustained earnings growth to justify further gains.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MMM
100% Buy0% Sell
Avg holding period · 169 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

Read more on MMM →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →